Gynecologic Oncology Reports最新文献

{"title":"Hysteroscopic endometrial laser ablation – A novel approach for palliative management of endometrial cancer in inoperable patients","authors":"Michael Lavie ,&nbsp;Gilad Rattan ,&nbsp;Dana Englander ,&nbsp;Shai Ram ,&nbsp;Neta Solomon ,&nbsp;Nadav Michaan ,&nbsp;Dan Grisaru ,&nbsp;Ido Laskov","doi":"10.1016/j.gore.2025.101728","DOIUrl":"10.1016/j.gore.2025.101728","url":null,"abstract":"<div><h3>Background</h3><div>Endometrial cancer, the most common gynecologic malignancy in developed nations, poses substantial treatment challenges, particularly in patients with significant comorbidities or advanced obesity.</div></div><div><h3>Purpose</h3><div>This manuscript introduces an innovative method that employs awake hysteroscopic endometrial laser ablation (HEA) as a palliative treatment for patients with endometrial cancer who were either inoperable or medically unfit to undergo general or regional anaesthesia for conventional therapies.</div></div><div><h3>Methods</h3><div>A retrospective evaluation of patients diagnosed with endometrial cancer at a tertiary center from 2019 to 2024, focusing on those with symptomatic uterine bleeding, who failed previous treatment options and could not undergo surgical or standard palliative interventions due to high surgical risk.</div></div><div><h3>Results</h3><div>In our study, three patients (n = 3) with severe medical conditions—high BMI and poor performance status—underwent awake HEA using a vaginoscopic approach, treating symptomatic vaginal bleeding effectively. The procedure allowed for rapid treatment, minimal recovery time, and enhanced quality of life. Histological analyses post-ablation indicated satisfactory outcomes, contributing to symptom relief and stabilization of patients’ conditions.</div></div><div><h3>Conclusion</h3><div>Our findings highlight the potential of conscious HEA as a palliative management strategy in high-risk patient populations, emphasizing its role when conventional therapies fail. This study underscores the importance of personalized treatment plans and multidisciplinary approaches in managing endometrial cancer, paving the way for further research into the safety and efficacy of HEA in similar cohorts.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101728"},"PeriodicalIF":1.2,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143703951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adnexal mass referral patterns in Gynecologic Oncology","authors":"Rusha Bajpai,&nbsp;Tammy Mundale,&nbsp;Natalia Gontarczyk Uczkowski,&nbsp;Amy Godecker,&nbsp;Stephen Rose","doi":"10.1016/j.gore.2025.101729","DOIUrl":"10.1016/j.gore.2025.101729","url":null,"abstract":"<div><h3>Objectives</h3><div>There is a perceived increase in adnexal mass referrals to Gynecologic Oncology that do not meet American College of Obstetricians and Gynecologists (ACOG) referral criteria. There is little data regarding referral patterns to Gynecologic Oncology. Our primary objective is to determine the proportion of consults meeting ACOG referral criteria over an eleven year period.</div></div><div><h3>Methods</h3><div>A retrospective chart review was conducted for adnexal mass referrals between 2011 and 2021. Variables such as age, menopausal status, imaging findings, tumor markers, surgery and histopathologic diagnosis determined whether the initial consult met ACOG referral criteria.</div></div><div><h3>Results</h3><div>A total of 864 new consults were reviewed, 84.7 % meeting ACOG referral criteria. When broken down by year, 82.0 %, 78.9 %, 82.2 %, 86.1 %, 92.6 % met criteria for the years 2011, 2012, 2016, 2018, 2021, respectively. There was a significantly higher proportion of consults meeting referral criteria in 2021 compared to 2011 (p = 0.003). In 2011, 37.8 % of surgical cases meeting ACOG criteria were malignant compared to 45.2 % in 2021 (p = 0.145).</div></div><div><h3>Conclusions</h3><div>Our service has seen an increasing proportion of adnexal mass referrals that meet ACOG referral criteria. There is also a trending increase in malignant histopathology. This may be due to increased scrutiny of referrals by gynecologic oncologists starting in 2016 with appropriate referral to benign gynecology. Improved scrutiny of adnexal mass referrals could decrease the number of benign cases evaluated by Gynecologic Oncology, helping preserve resources for patients with higher risk of malignancy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101729"},"PeriodicalIF":1.2,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four-year recurrence-free survival in metastatic uterine adenosarcoma with somatic BRCA2 mutation on olaparib therapy: A case report","authors":"Katie Foug ,&nbsp;Stephanie L. Skala ,&nbsp;Erica Stien ,&nbsp;Kevin Reynolds ,&nbsp;Jean Siedel ,&nbsp;Shitanshu Uppal","doi":"10.1016/j.gore.2025.101724","DOIUrl":"10.1016/j.gore.2025.101724","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101724"},"PeriodicalIF":1.2,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma","authors":"William Vintzileos,&nbsp;Hannah Beer,&nbsp;David Miller,&nbsp;Jayanthi Lea","doi":"10.1016/j.gore.2025.101722","DOIUrl":"10.1016/j.gore.2025.101722","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate and define the proportion of clinically stage I Uterine Carcinosarcoma (UCS) patients who are upstaged to FIGO stages II-IVB following primary surgery based on final pathology.</div></div><div><h3>Methods</h3><div>We performed a retrospective review of patients diagnosed and treated for UCS at our institution from 2009 to 2023. All patients who underwent primary surgery for UCS and had clinically stage I (uterine-confined) disease were included. Uterine-confined disease was determined based on pre-operative physical exam and imaging. The primary outcome was the proportion of patients who were upstaged after surgery.</div></div><div><h3>Results</h3><div>Ninety-eight patients underwent primary surgery with a median age of 64 years (IQR 59–68). Twenty-six patients (26.6 %) had suspected extra-uterine disease based on pre-operative evaluation and were excluded. Seventy-two patients (73.4 %) had uterine-confined disease based on pre-operative exam/imaging and underwent staging surgery. Of the 72 patients with clinical stage I disease, 39 patients (54.2 %) were ultimately diagnosed with advanced disease (FIGO Stages II-IVB), while 33 patients (45.8 %) had confirmed early-stage disease on final pathology (FIGO Stages IA or IB). Surgical staging revealed the following: 15.4 % (n = 6) were upstaged to Stage II, 5.1 % (n = 2) to Stage IIIA, 5.1 % (n = 2) to Stage IIIB, 35.9 % (n = 14) to Stage IIIC1, 12.8 % (n = 5) Stage IIIC2, and 25 % (n = 10) to Stage IVB.</div></div><div><h3>Conclusion</h3><div>More than 50% of patients with pre-operative “uterine-confined” carcinosarcoma were upstaged on final pathology, mostly commonly to Stage III. Our findings underscore the importance of surgical staging since upstaging carries critical prognostic information and implications for adjuvant treatment planning.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101722"},"PeriodicalIF":1.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of adjuvant therapy modality and treatment outcomes between appalachian and non-appalachian patients with high-risk endometrial carcinoma","authors":"Josie D. Llanora ,&nbsp;Gregory S. Hawk ,&nbsp;Laura M. Harbin ,&nbsp;Sara Lee ,&nbsp;Madison Lane ,&nbsp;Madison T. Hickey ,&nbsp;Elizabeth Pendygraft ,&nbsp;Lauren A. Baldwin ,&nbsp;Megan L. Hutchcraft","doi":"10.1016/j.gore.2025.101725","DOIUrl":"10.1016/j.gore.2025.101725","url":null,"abstract":"<div><h3>Objective</h3><div>The incidence and mortality of endometrial cancer is increasing. After surgical staging, patients with high-risk disease often undergo adjuvant treatment, which may include systemic therapy, radiation therapy, or combined modalities. Patients in rural Appalachia have limited access to subspecialty care needed for optimal disease management. This study aims to compare adjuvant treatment regimens and outcomes among patients with high-risk endometrial cancer living in Appalachian and non-Appalachian regions.</div></div><div><h3>Methods</h3><div>We retrospectively identified 179 patients with high-risk endometrial carcinoma who underwent surgical staging at a single academic medical center and received adjuvant therapy between 2012 and 2019. Patients were identified as Appalachian (n = 119) and non-Appalachian (n = 60) residents based on home ZIP code. Adjuvant therapy regimen, recurrence rate, recurrence location, progression free survival (PFS), and overall survival (OS) were compared. Statistical comparisons were performed using multinomial and ordinal logistic regression models, Kaplan-Meier curves, Log Rank test, two-sample t-tests, Fisher’s exact, and chi-square tests.</div></div><div><h3>Results</h3><div>There was no significant difference in adjuvant therapy regimen between groups. Overall recurrence rates were similar, though rate of vaginal recurrence was higher among non-Appalachian patients compared to Appalachian patients (42 % vs. 14 %, p = 0.05). There were no differences in rate of pelvic or distant recurrences, PFS, or OS.</div></div><div><h3>Conclusion</h3><div>Despite lower densities of subspecialists in rural Appalachia, Appalachian and non-Appalachian patients with high-risk endometrial cancer received similar adjuvant therapy regimens and had similar disease outcomes. Further efforts should work to optimize treatment and surveillance for patients with endometrial carcinoma with barriers to subspecialty care.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101725"},"PeriodicalIF":1.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143696790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies","authors":"Khrystyna Levytska ,&nbsp;R. Wendel Naumann ,&nbsp;Miranda J. Benfield ,&nbsp;Jubilee Brown ,&nbsp;Yovanni Casablanca ,&nbsp;Brittany Lees ,&nbsp;Allison M. Puechl ,&nbsp;Erin K. Crane","doi":"10.1016/j.gore.2025.101727","DOIUrl":"10.1016/j.gore.2025.101727","url":null,"abstract":"<div><h3>Objective</h3><div>Although pegylated liposomal doxorubicin (PLD) has a more favorable side-effect profile compared to doxorubicin, the FDA label for PLD includes a warning listing cardiotoxicity. Our objective was to evaluate predictors of pre- and post-treatment cardiac testing and quantify the effect of PLD on cardiac function in patients treated for gynecologic malignancies.</div></div><div><h3>Methods</h3><div>Retrospective chart review of gynecologic oncology patients who received PLD over a 10-year period at a single institution. Cardiac studies were aligned to PLD treatment and ejection fractions (EF) were compared pre- and post-treatment.</div></div><div><h3>Results</h3><div>A total of 453 patients who had received PLD were identified; 216 (48 %) had pre-PLD treatment cardiac function testing. Predictors of pre-chemotherapy testing were diabetes (p = 0.015), higher ECOG score (p = 0.004), and cardiac disease (p = 0.032). Eighty-three (18.3 %) patients had pre- and post-PLD treatment cardiac function testing. Predictors of pre- and post- testing were number of cycles of PLD (p &lt; 0.0001) and total dose of PLD (p &lt; 0.0001). Seventy-five (90 %) patients had no change in EF (defined as &lt; 10 %), while 2 (2.4 %) had improvement in EF &gt; 10 %, and 6 (7.2 %) had a decrease in EF &gt; 10 %. Initial EF in patients with &gt; 10 % decrease was higher than in those without change or improvement (p = 0.0004). One (1.2 %) patient had a clinically significant decrease in EF (32.5 %) resulting in interruption of treatment.</div></div><div><h3>Conclusion</h3><div>Risk of cardiac toxicity from administration of PLD for patients undergoing treatment for gynecologic cancers appears to be low. Selective screening of cardiac function should be employed for these patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101727"},"PeriodicalIF":1.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple synchronous primary cancers comprising large cell neuroendocrine carcinoma of the lower uterine segment and endometrioid carcinomas of the uterine corpus and the right ovary-a rare combination: A case report","authors":"Kaichiro Yamamoto ,&nbsp;Shin-ichi Nakatsuka ,&nbsp;Tomochika Goto ,&nbsp;Reiko Samoto ,&nbsp;Aki Minami ,&nbsp;Masatoshi Imamura","doi":"10.1016/j.gore.2025.101721","DOIUrl":"10.1016/j.gore.2025.101721","url":null,"abstract":"<div><div>We report a rare case of triple primary cancers in a 52-year-old woman who presented with abdominal pain and fever. Diagnostic imaging and subsequent histopathological evaluation revealed independent primary endometrioid carcinomas of the ovary and uterine corpus proper (UC), as well as large cell neuroendocrine carcinoma (LCNEC) originating from the lower uterine segment (LUS). Surgical resection was performed, followed by adjuvant chemotherapy (irinotecan and cisplatin). The patient demonstrated no recurrence at the 10-month follow-up.</div><div>This case highlights the importance of accurate pathological differentiation, as prognosis and treatment depend on distinguishing independent primary tumors from metastatic lesions. This rare case of triple synchronous malignancies emphasizes the need for a multidisciplinary approach to ensure precise diagnosis and optimal management. Comprehensive molecular studies and advanced imaging techniques may further improve outcomes in such complex cases.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101721"},"PeriodicalIF":1.2,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of diet, obesity and body composition in epithelial ovarian cancer development and progression: Mechanisms and therapeutic implications","authors":"Jessica Suratkal ,&nbsp;Theresa D’Silva ,&nbsp;Mariam AlHilli","doi":"10.1016/j.gore.2025.101718","DOIUrl":"10.1016/j.gore.2025.101718","url":null,"abstract":"<div><div>Epithelial ovarian cancer (EOC) ranks among the deadliest cancers, with over half of newly diagnosed patients presenting with metastatic disease, highlighting the need for early detection strategies and a deeper understanding of biologic factors that impact EOC progression and treatment response. This paper aims to synthesize the current literature on the association between diet, obesity, and body composition and EOC prognosis, drawing on translational, molecular, and clinical studies to identify gaps in research and inform preventative strategies to improve outcomes in EOC patients. The current literature on the association between diet and EOC prognosis suggests a role for several dietary interventions in the prevention of EOC development and progression, including increased intake of animal-based proteins (specifically dairy products), fiber-rich foods, cruciferous vegetables, and polyunsaturated fats, and ongoing clinical trials examine variations of intermittent fasting and fasting-mimicking diets in EOC patients. However, the impact of diet and nutritional interventions on survival and therapeutic response in EOC remains largely understudied, and low quality of evidence in this area limits the ability to form comprehensive dietary recommendations. Therefore, this study calls for future research in this area to inform dietary recommendations with the ultimate goals of improving patient outcomes and quality of life. Additionally, obesity and high-fat diets may contribute to EOC progression through chronic low-grade inflammation, and consideration of body composition and adiposity may impact intervention parameters and should be investigated in future research.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101718"},"PeriodicalIF":1.2,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience of healthcare discrimination reported by individuals with a history of gynecologic cancer in the All of Us research program","authors":"Allison C. Dona ,&nbsp;Patricia I. Jewett ,&nbsp;Sarah Davidson ,&nbsp;Deanna Teoh ,&nbsp;Rachel I. Vogel","doi":"10.1016/j.gore.2025.101723","DOIUrl":"10.1016/j.gore.2025.101723","url":null,"abstract":"<div><h3>Objective</h3><div>We aimed to describe prevalence of healthcare discrimination in <em>All of Us</em> participants with a history of gynecologic cancer and compare patient experiences of discrimination by gynecologic cancer type.</div></div><div><h3>Methods</h3><div>We analyzed survey data of participants with a history of gynecologic cancer in the <em>All of Us Research Program</em>. Cancer status was defined using self-report or electronic health record documentation. Healthcare discrimination was measured by the Discrimination in Medical Settings (DMS) Scale. Potential confounders were self-reported (cigarette use, sexual orientation, gender, race, ethnicity, income, education, and age) and physical measurement (body mass index). We report associations between gynecologic cancer site (cervical, ovarian, uterine, vaginal or vulvar, more than one) and DMS scores using multivariable logistic regression.</div></div><div><h3>Results</h3><div>Of 2,195 participants, 1,001 had cervical, 579 uterine, 419 ovarian, 30 vaginal/vulvar, and 166 more than one gynecologic cancer. Most (76.5%) reported experiencing any healthcare discrimination, and 45.0% reported frequent healthcare discrimination. Those with a history of cervical cancer (52%, OR: 1.80, 95% CI: 1.42, 2.28) and multiple cancers (47.8%, OR: 1.53, 95% CI: 1.05, 2.21) had higher odds of frequently reporting discrimination than those with a history of ovarian cancer (37.5%) in the unadjusted model. The relationship observed remained but was attenuated in the adjusted model (Cervical OR: 1.35, 95% CI: 1.04, 1.75; Multiple OR: 1.35 95% CI: 0.91, 2.00).</div></div><div><h3>Conclusions</h3><div>Healthcare discrimination was reported across cancer types. Individuals with a history of cervical or multiple gynecologic malignancies reported frequent healthcare discrimination more often than those with other gynecologic cancers.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101723"},"PeriodicalIF":1.2,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological impact of risk-reducing surgery for gynecologic cancer among women with Lynch syndrome","authors":"Helen Huband ,&nbsp;Kaitlin M McGarragle ,&nbsp;Crystal J Hare ,&nbsp;Melyssa Aronson ,&nbsp;Thomas Ward ,&nbsp;Kara Semotiuk ,&nbsp;Sarah E Ferguson ,&nbsp;Zane Cohen ,&nbsp;Tae L Hart","doi":"10.1016/j.gore.2025.101719","DOIUrl":"10.1016/j.gore.2025.101719","url":null,"abstract":"<div><h3>Objective</h3><div>Prophylactic total hysterectomy and bilateral salpingo-oophorectomy are risk-reducing surgeries (RRS) that can be offered to women with Lynch syndrome (LS) as they reduce the incidence of ovarian and endometrial cancer. Few studies have examined facilitators to RRS or the experiences of women with LS post-surgery. This qualitative study explored the experiences of women with LS who underwent RRS.</div></div><div><h3>Methods</h3><div>Women with LS who had undergone RRS within the prior 10 years were recruited from a genetic cancer registry and a tertiary care medical centre in Canada. Participants completed interviews over the phone. A qualitative descriptive methodological approach was taken, and interviews were analyzed using thematic analysis.</div></div><div><h3>Results</h3><div>Fifteen participants completed interviews. Themes identified included: 1) facilitators to RRS including desire for peace of mind, completed family planning, presence of physical symptoms associated with gynecologic cancer, burden of screening, personal or family history of cancer, age, and trust in healthcare providers (HCPs); 2) women’s experiences with RRS including post-surgical recovery, long-term physical changes post-surgery, impact of surgery on sexual health, psychological impacts of managing risk, and post-surgical care from HCPs; 3) experiences managing menopausal symptoms and use of hormone replacement therapy; and 4) unmet informational needs including managing expectations prior to surgery, understanding risk related to other health conditions, and questions about the ongoing need for gynecologic cancer surveillance.</div></div><div><h3>Conclusions</h3><div>HCPs should consider facilitators to surgery in women with LS contemplating RRS. HCPs should also provide women with LS more detailed post-surgery information on what to expect, and risks of other health conditions.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101719"},"PeriodicalIF":1.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}